ELEPHAS BIOSCIENCES ANNOUNCES EXCLUSIVE COMMERCIAL PARTNERSHIP IN INDIA WITH NEUBERG DIAGNOSTICS

Elephas Biosciences Corporation, a privately held firm recognized for its groundbreaking live tissue platform dedicated to predicting immunotherapy responses, has announced a pivotal exclusive partnership with Neuberg Diagnostics, a prominent pathology and molecular diagnostics group based in India. This collaboration signifies a substantial advancement in Elephas’ global commercialization strategy, extending crucial access to personalized oncology solutions within the Indian market.

The agreement designates Neuberg as Elephas’ exclusive commercial partner in India, aligning with Elephas’ ongoing pursuit of strategic international alliances that share its commitment to enhancing outcomes for patients undergoing immunotherapy. As part of this partnership, Neuberg will integrate the innovative elive™ platform into its existing laboratory infrastructure, with an ambitious target of launching its own clinical test in India by the close of 2026. This initiative is set to revolutionize cancer treatment by providing oncologists with a more holistic understanding of the disease, merging Neuberg’s established proficiency in oncology diagnostics with Elephas’ advanced functional research platform. This synergistic approach will combine traditional molecular profiling with dynamic live tumor functional testing.

Beyond the commercial facet, Neuberg will also serve as Elephas’ research partner in India. This involves processing tumor biopsy samples using the elive platform at Neuberg’s leading laboratory in Ahmedabad. This research endeavor is anticipated to generate vital local evidence, substantiating the platform’s efficacy and performance as it moves towards wider adoption across the region.

Maneesh Arora, founder and CEO of Elephas, expressed considerable enthusiasm for the partnership, highlighting Neuberg Diagnostics’ strong leadership in oncology diagnostics and its significant footprint across India. Arora emphasized that the combination of Neuberg’s molecular diagnostics expertise with the elive platform creates a robust foundation for integrating functional immunotherapy response assessment into routine oncology care throughout India.

Dr. Sandip Shah, Joint Managing Director of Neuberg Diagnostics, underscored the critical challenge in cancer care: accurately identifying which patients will respond to immunotherapy. He emphasized that the integration of functional response data with molecular profiling will instill greater confidence in clinicians, enabling them to guide patients toward the most effective therapies more swiftly.

Elephas Biosciences positions itself as a global leader in functional precision medicine, with its elive™ platform representing a significant breakthrough in live-tissue technology designed to evaluate therapeutic responses across various oncology treatments. The global burden of cancer is escalating, with projections indicating a threefold increase in patient numbers by 2060. Despite the proliferation of immunotherapies and targeted therapies, only a fraction of patients experience a positive response, and many who might benefit are disqualified due to the absence of precise predictive biomarkers. To address this growing dilemma, Elephas has engineered an ex vivo platform capable of assessing how live tumor tissue reacts to oncology therapies. By meticulously preserving the native tumor microenvironment obtained from live core needle biopsies and employing a novel methodology to tackle tumor heterogeneity, the elive™ platform delivers a functional readout, providing invaluable insights that inform crucial treatment decisions. Further details about Elephas can be found on their official website and LinkedIn page.

Neuberg Diagnostics, headquartered in Chennai, stands as a premier diagnostic service provider in India, with operations extending to the UAE, South Africa, and the USA. Its laboratories hold prestigious accreditations from CAP and NABL. The group has democratized access to cutting-edge diagnostic technologies, boasting a team of distinguished clinical pathologists, oncopathologists, biochemists, geneticists, and other certified clinical lab professionals. This expert team is equipped to perform over 6,000 distinct pathological investigations. Neuberg is deeply committed to prevention, wellness programs, and structured disease management initiatives for rare diseases, leveraging advanced technologies augmented by data science and AI tools. Presently, Neuberg processes more than 30 million tests annually, delivering high-quality reports through an extensive network of over 250 laboratories across India.